Abstract
The aim. The study was to evaluate the effectiveness and safety of co-administration of antituberculosis and antiviral therapy (AVT) in patients with coinfection of chronic viral hepatitis C and pulmonary tuberculosis. Materials and methods. The observational study included 52 patients with active tuberculosis (63.5% drug-resistant cases) and chronic viral hepatitis C; 11 of them received a course of antiviral therapy (pan-genotypic regimens), 8 patients – simultaneously with anti-tuberculosis treatment (ATT, regimens without rifampicin), another 3 – before the start of tuberculosis treatment. Results. All 8 patients (100%) who received simultaneous AVT and ATT demonstrated a virological response; 7 days after the start of AVT, a complete normalization of transaminase levels was observed, which made it possible to prescribe an adequate ATT regimen and achieve successful treatment of tuberculosis. Two patients experienced mild adverse reactions, including transient eosinophilia, associated with the use of anti-tuberculosis drugs. After AVT, liver enzyme levels remained normal until completion of anti-tuberculosis treatment; in group without AVT (n = 41), the incidence of drug-induced liver injury was 61.0% (p < 0.001). Conclusion. Co-administration of anti-tuberculosis and antiviral therapy in tuberculosis patients with chronic hepatitis C is safe and effective. Pangenotypic AVT regimens are optimal. It is better to start including anti-tuberculosis drugs from the second week of antiviral treatment.

This publication has 23 references indexed in Scilit: